Nitrate-nitrite-nitric oxide pathway

The nitrate-nitrite-nitric oxide pathway is a metabolic/signaling cascade that provides an alternative route for the generation of bioactive nitric oxide (NO) independent of the classical L‑arginine–NO synthase system. In this non-canonical route: Dietary or endogenous nitrate (\\( \\text{NO}_3^- \\)) is first reduced to nitrite (\\( \\text{NO}_2^- \\))—primarily by commensal oral bacteria—and then further reduced to NO within tissues via several enzymatic systems under low oxygen or acidic conditions.[3][4][6] This mechanism becomes particularly important when oxygen-dependent NO synthases are impaired or during hypoxia. This pathway plays critical roles in cardiovascular homeostasis—including blood pressure regulation and tissue protection during ischemic events—by ensuring continued production of vasodilatory NO even when canonical synthesis is compromised. It has therapeutic implications for hypertension, heart failure with preserved ejection fraction (HFpEF), pulmonary hypertension, stroke recovery, metabolic syndrome reversal in animal models,[6] and possibly exercise performance enhancement. While not a single molecular target like an enzyme or receptor but rather a physiological/metabolic process involving multiple molecules and enzymes,[3] it remains highly relevant as a therapeutic axis modulated by drugs such as organic nitrates/nitrites and dietary interventions. Because this entry refers to an entire *pathway*, not a discrete molecular target such as an enzyme or receptor protein—and thus does not fit standard drug-target classification—the field “is_target” should be set to false; “is_incorrect” should be set true if only individual proteins/enzymes/receptors are considered valid targets per your conventions.[3]

Other names

Nitrate–nitrite–NO pathwayNitrate reduction pathwayNitrite reduction pathwayNon-canonical nitric oxide generation pathway

1. Nitrate is reduced to nitrite by oral bacteria with nitrate reductase activity. 2. Nitrite is further reduced to nitric oxide in tissues, especially under acidic or hypoxic conditions, via various mammalian enzymes such as hemoglobin, myoglobin, xanthine oxidase, aldehyde oxidase, and mARC. 3. Resulting nitric oxide mediates vasodilation, cytoprotection, and other effects through activation of soluble guanylate cyclase and cGMP signaling.